Meithal Pharmaceuticals has revealed plans to expand its manufacturing capabilities, at the same time as the US Food and Drug Administration approved a new vial manufacturing line in China that will double the firm’s capacity to supply the US market.
The new manufacturing line and future expansion plans “will significantly increase production capacity of heparin, amidst